CR20190431A - Formatos mejorados de receptor de unión a antígeno - Google Patents

Formatos mejorados de receptor de unión a antígeno

Info

Publication number: CR20190431A
Authority: CR; Costa Rica
Prior art keywords: antígeno; unión; antigen binding; invención; antigen
Prior art date: 2017-03-27

Application number

CR20190431A

Other languages

English (en)

Inventor

Diana Darowski

Christian Klein

Ekkehard Moessner

Kay-Gunnar Stubenrauch

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-03-27

Filing date

2018-03-26

Publication date

2019-11-01

2018-03-26 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2019-11-01 Publication of CR20190431A publication Critical patent/CR20190431A/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4221—CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CR20190431A 2017-03-27 2018-03-26 Formatos mejorados de receptor de unión a antígeno CR20190431A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP17163090		2017-03-27
EP17171775		2017-05-18
PCT/EP2018/057567 WO2018177967A1 (en)	2017-03-27	2018-03-26	Improved antigen binding receptor formats

Publications (1)

Publication Number	Publication Date
CR20190431A true CR20190431A (es)	2019-11-01

Family

ID=61800534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20190431A CR20190431A (es)	2017-03-27	2018-03-26	Formatos mejorados de receptor de unión a antígeno

Country Status (19)

Country	Link
US (1)	US20200093861A1 (es)
EP (1)	EP3600408A1 (es)
JP (1)	JP2020511979A (es)
KR (1)	KR20190133017A (es)
CN (1)	CN110461360A (es)
AU (1)	AU2018241625A1 (es)
BR (1)	BR112019017629A2 (es)
CA (1)	CA3054104A1 (es)
CL (1)	CL2019002686A1 (es)
CR (1)	CR20190431A (es)
IL (1)	IL268824A (es)
MA (1)	MA49355A (es)
MX (1)	MX2019011656A (es)
PE (1)	PE20191703A1 (es)
RU (1)	RU2019133199A (es)
SG (1)	SG11201908784TA (es)
TW (1)	TW201900672A (es)
WO (1)	WO2018177967A1 (es)
ZA (1)	ZA201905519B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP7022123B2 (ja) *	2016-09-30	2022-02-17	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｃｄ３に対する二重特異性抗体
CN108395482B (zh)	2017-02-08	2021-02-05	西比曼生物科技（香港）有限公司	一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
MX2019011526A (es)	2017-03-27	2019-12-05	Hoffmann La Roche	Receptores de union a antigeno mejorados.
WO2020127618A1 (en)	2018-12-21	2020-06-25	F. Hoffmann-La Roche Ag	Tumor-targeted agonistic cd28 antigen binding molecules
JP2022513495A (ja) *	2018-12-21	2022-02-08	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子
CN110317277A (zh) *	2019-07-10	2019-10-11	杭州普科亭生物医药有限公司	嵌合抗原受体及其应用
EP4028414A4 (en) *	2019-09-11	2024-01-17	The Trustees of The University of Pennsylvania	Compositions and methods comprising prostate stem cell antigen (psca) chimeric antigen receptors (cars)
EP4110829A4 (en) *	2020-02-27	2024-06-05	Sorrento Therapeutics, Inc.	DIMER ANTIGEN RECEPTORS (DAR) BINDING TO CD20
CN113402612A (zh)	2020-03-17	2021-09-17	西比曼生物科技（香港）有限公司	靶向cd19和cd20的联合嵌合抗原受体及其应用
KR20230006823A (ko) *	2020-04-30	2023-01-11	치아타이 티안큉 파마수티컬 그룹 주식회사	Her2를 표적화하는 항원 결합 구조체 및 이의 용도
WO2022036065A2 (en) *	2020-08-13	2022-02-17	A2 Biotherapeutics, Inc.	Compositions and methods for treating cancers
EP4100028A4 (en)	2020-08-20	2023-07-26	A2 Biotherapeutics, Inc.	Compositions and methods for treating mesothelin positive cancers
EP4097486A4 (en) *	2020-08-20	2023-09-06	A2 Biotherapeutics, Inc.	COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM
CN114990129B (zh) *	2022-05-11	2023-02-03	北京贝来生物科技有限公司	表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
WO2024098940A1 (zh) *	2022-11-07	2024-05-16	北京伟德杰生物科技有限公司	双特异性抗体及其应用
AU2024244733B2 (en)	2023-03-31	2025-12-11	AbelZeta Inc.	Bispecific chimeric antigen receptors targeting cd20 and bcma
TW202545991A (zh) *	2024-01-12	2025-12-01	大陸商信達生物製藥（蘇州）有限公司	抗ｃｄ２８抗體及其用途
CN118956629A (zh) *	2024-07-24	2024-11-15	佳吾益(北京)科技有限公司	表达真正表位接受型mhc胞外结构域的工程化细胞

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI903489A0 (fi)	1988-11-11	1990-07-10	Medical Res Council	Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
GB9304200D0 (en)	1993-03-02	1993-04-21	Sandoz Ltd	Improvements in or relating to organic compounds
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69333807T2 (de)	1992-02-06	2006-02-02	Chiron Corp., Emeryville	Marker für krebs und biosynthetisches bindeprotein dafür
DE69434447T2 (de)	1993-06-07	2006-05-18	Vical, Inc., San Diego	Für die gentherapie verwendbare plasmide
JPH11509088A (ja)	1995-06-23	1999-08-17	プレジデントアンドフェローズオブハーバードカレッジ	血管内皮増殖因子受容体をコードする遺伝子の転写調節
WO2001044463A1 (en)	1999-12-15	2001-06-21	Genentech, Inc.	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP4753578B2 (ja)	2002-06-03	2011-08-24	ジェネンテック，インコーポレイテッド	合成抗体ファージライブラリー
US20050079574A1 (en)	2003-01-16	2005-04-14	Genentech, Inc.	Synthetic antibody phage libraries
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
BRPI0607315B1 (pt)	2005-02-07	2022-05-17	Roche Glycart Ag	Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
EP1957531B1 (en)	2005-11-07	2016-04-13	Genentech, Inc.	Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en)	2005-12-02	2008-10-01	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en)	2006-05-09	2007-11-22	Genentech, Inc.	Binding polypeptides with optimized scaffolds
CN100592373C (zh)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	液晶显示面板驱动装置及其驱动方法
US8242247B2 (en) *	2007-12-21	2012-08-14	Hoffmann-La Roche Inc.	Bivalent, bispecific antibodies
WO2010012829A1 (en)	2008-07-31	2010-02-04	Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh)	Her2/neu specific t cell receptors
BR112013018311A2 (pt) *	2011-01-18	2017-03-21	Univ Pennsylvania	sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
BR112013024574B1 (pt)	2011-03-29	2022-08-09	Roche Glycart Ag	Anticorpo e uso do anticorpo
PH12013502531A1 (en) *	2011-08-23	2014-01-20	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
RU2693264C2 (ru) *	2012-02-03	2019-07-01	Ф.Хоффман-Ля Рош Аг	Молекулы биспецифических антител и т-клетки, трансфецированные антигеном, и их применение в медицине
WO2014055771A1 (en) *	2012-10-05	2014-04-10	The Trustees Of The University Of Pennsylvania	Human alpha-folate receptor chimeric antigen receptor
EP3119425B1 (en) *	2014-03-15	2020-09-23	Novartis AG	Regulatable chimeric antigen receptor
UA117289C2 (uk)	2014-04-02	2018-07-10	Ф. Хоффманн-Ля Рош Аг	Мультиспецифічне антитіло
WO2015179833A1 (en) *	2014-05-23	2015-11-26	The Trustees Of The University Of Pennsylvania	Compositions and methods for treating antibody resistance
WO2015179801A1 (en) *	2014-05-23	2015-11-26	University Of Florida Research Foundation, Inc.	Car based immunotherapy
DK3151672T3 (da) *	2014-06-06	2021-02-01	Bluebird Bio Inc	Forbedrede t-celle-sammensætninger
SMT202400235T1 (it)	2014-08-04	2024-07-09	Hoffmann La Roche	Molecole bispecifiche leganti l’antigene di attivazione delle cellule t
KR20170073593A (ko) *	2014-09-09	2017-06-28	유넘 테라퓨틱스	키메라 수용체 및 면역 요법에서의 그의 용도
US11161907B2 (en) *	2015-02-02	2021-11-02	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
CA2986030A1 (en)	2015-05-15	2016-11-24	City Of Hope	Chimeric antigen receptor compositions
WO2017011316A1 (en) *	2015-07-10	2017-01-19	The Trustees Of The University Of Pennsylvania	Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor
KR20180040706A (ko) *	2015-09-01	2018-04-20	인네이트 튜머 이뮤니티, 인코포레이티드	면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도
CA3000242A1 (en) *	2015-10-01	2017-04-06	The Centre For Drug Research And Development	Anti-podocalyxin antibodies and methods of using the same
CN110352198B (zh) *	2016-10-19	2024-03-26	多伦多大学管理委员会	Cd133结合剂及其用途
JOP20180027A1 (ar) *	2017-03-28	2019-01-30	Cell Design Labs Inc	بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
CN107337737B (zh) *	2017-07-18	2020-02-07	深圳市免疫基因治疗研究院	一种嵌合抗原受体及其应用

2018
- 2018-03-26 CA CA3054104A patent/CA3054104A1/en active Pending
- 2018-03-26 KR KR1020197030317A patent/KR20190133017A/ko not_active Ceased
- 2018-03-26 MA MA049355A patent/MA49355A/fr unknown
- 2018-03-26 RU RU2019133199A patent/RU2019133199A/ru unknown
- 2018-03-26 CN CN201880021542.3A patent/CN110461360A/zh active Pending
- 2018-03-26 JP JP2019552992A patent/JP2020511979A/ja active Pending
- 2018-03-26 SG SG11201908784T patent/SG11201908784TA/en unknown
- 2018-03-26 MX MX2019011656A patent/MX2019011656A/es unknown
- 2018-03-26 BR BR112019017629A patent/BR112019017629A2/pt not_active IP Right Cessation
- 2018-03-26 AU AU2018241625A patent/AU2018241625A1/en not_active Abandoned
- 2018-03-26 PE PE2019001939A patent/PE20191703A1/es unknown
- 2018-03-26 EP EP18713648.6A patent/EP3600408A1/en not_active Withdrawn
- 2018-03-26 WO PCT/EP2018/057567 patent/WO2018177967A1/en not_active Ceased
- 2018-03-26 TW TW107110206A patent/TW201900672A/zh unknown
- 2018-03-26 CR CR20190431A patent/CR20190431A/es unknown
2019
- 2019-08-21 IL IL26882419A patent/IL268824A/en unknown
- 2019-08-21 ZA ZA2019/05519A patent/ZA201905519B/en unknown
- 2019-09-19 US US16/576,586 patent/US20200093861A1/en not_active Abandoned
- 2019-09-23 CL CL2019002686A patent/CL2019002686A1/es unknown

Also Published As

Publication number	Publication date
JP2020511979A (ja)	2020-04-23
IL268824A (en)	2019-10-31
MX2019011656A (es)	2019-12-02
ZA201905519B (en)	2021-06-30
CL2019002686A1 (es)	2020-02-14
US20200093861A1 (en)	2020-03-26
EP3600408A1 (en)	2020-02-05
RU2019133199A3 (es)	2021-07-09
MA49355A (fr)	2020-02-05
WO2018177967A1 (en)	2018-10-04
TW201900672A (zh)	2019-01-01
KR20190133017A (ko)	2019-11-29
BR112019017629A2 (pt)	2020-04-07
RU2019133199A (ru)	2021-04-28
PE20191703A1 (es)	2019-11-27
SG11201908784TA (en)	2019-10-30
CN110461360A (zh)	2019-11-15
CA3054104A1 (en)	2018-10-04
AU2018241625A1 (en)	2019-09-05

Publication	Publication Date	Title
CR20190431A (es)	2019-11-01	Formatos mejorados de receptor de unión a antígeno
CL2021000717A1 (es)	2021-10-15	Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CO2020008972A2 (es)	2020-07-31	Nanopartícula de lípido que contiene ácido nucleico y uso de la misma
CL2019002717A1 (es)	2020-02-21	Receptores de unión a antígeno mejorados.
MX2025009210A (es)	2025-09-02	Anticuerpos de b7-h4 y metodos para usarlos
MX2018010733A (es)	2019-07-04	Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
CY1123355T1 (el)	2021-12-31	Αντισωματα εναντι cd73 και χρησεις εξ αυτων
MX2024001192A (es)	2024-05-31	Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
MX366965B (es)	2019-07-31	Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
MX2017001011A (es)	2018-05-28	Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
EP4303229A3 (en)	2024-04-17	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
BR112015019603A2 (pt)	2017-08-22	Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
ECSP14004893A (es)	2015-06-30	Moléculas de unión para bcma y cd3
CL2017002641A1 (es)	2018-04-27	Construcciones de anticuerpos biespecíficos contra cdh3 y cd3
MX2017001403A (es)	2017-07-07	Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
MX2017001008A (es)	2017-08-02	Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2019012017A (es)	2020-02-12	Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
PE20181013A1 (es)	2018-06-26	Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
CR20190095A (es)	2019-06-13	Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos
MX2017001402A (es)	2017-08-28	Constructos de anticuerpos para cdh19 y cd3.
PE20151613A1 (es)	2015-11-14	Construcciones de anticuerpos para cdh19 y cd3
MX2015012862A (es)	2016-05-31	Moleculas de union para bcma y cd3.
AR080873A1 (es)	2012-05-16	Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3)
MX388904B (es)	2025-03-20	Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
BR112015021819A2 (pt)	2017-08-29	Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19